menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Institute of Materia Medica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica","highestDevelopmentStatusID":"4","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Lynk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Simcere Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Simcere","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Simcere"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Daridorexant","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Simcere Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Simcere Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SSD8432","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Mass General Brigham","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Mass General Brigham","highestDevelopmentStatusID":"2","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Mass General Brigham"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Connect Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Rademikibart","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"SIM0500","moa":"GPRC5D\/BCMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":1.0600000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.0600000000000001,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Abbvie Inc"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Guangzhou Fermion Technology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"FZ002-037","moa":"SSTR4","graph1":"Neurology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"SIM0235","moa":"||TNFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Jiangsu Simcere Pharmaceutical

    Menu

    Jiangsu Simcere Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FZ002-037

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Guangzhou Fermion Technology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Fermion, Simcere Exclusive License for China’s First SSTR4 Agonist

                            Details : Under the agreement, Simcere will gain exclusive rights to develop and commercialize FZ002-037 in Greater China. It is being evaluated for the treatment of Chronic Pain.

                            Product Name : FZ002-037

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 17, 2025

                            Lead Product(s) : FZ002-037

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Guangzhou Fermion Technology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIM0500

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $1,055.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AbbVie Pens $1B deal for Simcere’s Phase 1 T-Cell Engager

                            Details : Simcere has option to license agreement with Abbvie to develop SIM0500, an investigational new drug candidate. It is being evaluated in patients with relapsed or refractory multiple myeloma.

                            Product Name : SIM0500

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : SIM0500

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $1,055.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Simcere’s Sanbexin® Approved in China for Acute Ischemic Stroke

                            Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 04, 2024

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sanbexin Sublingual Tablets Receive Breakthrough Therapy Designation from FDA

                            Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.

                            Product Name : Sanbexin

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 05, 2024

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab,Irinotecan Hydrochloride,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA

                            Details : Enlituo (cetuximab beta) is a EGFR inhibitor indicated in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC).

                            Product Name : Enlituo

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 26, 2024

                            Lead Product(s) : Cetuximab,Irinotecan Hydrochloride,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Neurodawn Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

                            Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.

                            Product Name : Sanbexin

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 20, 2024

                            Lead Product(s) : Edaravone,Dexborneol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Neurodawn Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rademikibart

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Connect Biopharma

                            Deal Size : $141.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

                            Details : Under the agreement, Simcere will develop and commercialize Connect Biopharma’s CBP-201 (rademikibart), a human monoclonal antibody against IL-4Rα, in Greater China.

                            Product Name : CBP-201

                            Product Type : Large molecule

                            Upfront Cash : $21.0 million

                            November 21, 2023

                            Lead Product(s) : Rademikibart

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Connect Biopharma

                            Deal Size : $141.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Mass General Brigham

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham

                            Details : The agreement aims to establish a mutually beneficial partnership that will advance scientific research and create new treatment options for patients with cancer, autoimmune and CNS diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Mass General Brigham

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIM0235,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combinat...

                            Details : Under the agreement, MSD will supply KEYTRUDA and collaborate with Simcere to evaluate the combination of SIM0235, a potential first-in-class humanized anti-TNFR2 mAb, and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced sol...

                            Product Name : SIM0235

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            March 14, 2023

                            Lead Product(s) : SIM0235,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SSD8432,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase II/III Clinical Trial of Simcere's 3CL-Targeting Anti-SARS-COV-2 Drug Candidate Complete All Patients En...

                            Details : XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate SSD8432 and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.

                            Product Name : Xiannuoxin

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2022

                            Lead Product(s) : SSD8432,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth